A Multicenter, Randomized, Double-Blind, Flexible-Dose, Long-Term Extension Trial of the Safety and Maintenance of Effect of Asenapine Using Olanzapine Positive Control in Subjects Who Complete Protocols 041021 or 041022.

Trial Profile

A Multicenter, Randomized, Double-Blind, Flexible-Dose, Long-Term Extension Trial of the Safety and Maintenance of Effect of Asenapine Using Olanzapine Positive Control in Subjects Who Complete Protocols 041021 or 041022.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jun 2014

At a glance

  • Drugs Asenapine (Primary) ; Olanzapine
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Schering-Plough
  • Most Recent Events

    • 06 Oct 2009 Additional lead trial centre (Schering-Plough) identified as reported by ClinicalTrials.gov.
    • 18 Aug 2008 Trial identifier 041512 changed to 41512 as reported by ClinicalTrials.gov.
    • 18 Aug 2008 Primary endpoint added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top